Bailey L L, Gundry S R, Razzouk A J, Wang N, Sciolaro C M, Chiavarelli M
Department of Surgery, Loma Linda University and Medical Center, CA 92354.
J Thorac Cardiovasc Surg. 1993 May;105(5):805-14; discussion 814-5.
There is a rapid growth of interest in heart transplantation therapy during early infancy. From 10% to 25% of the infants who are listed for transplantation annually have died while awaiting a donor heart. There has been no significant trend in this variable. Since November 1985, 140 consecutive orthotopic transplantation procedures were performed in 139 infants who were from 3 hours to 12 months of age. Indications for transplantation included hypoplastic left heart syndrome (63%), other complex structural anomalies (29%), myopathy (6.5%), and tumors (1.5%). Most recipients had ductus-dependent circulation and received continuous infusion of prostaglandin E1. Heart donors were usually victims of trauma, sudden infant death, or birth asphyxia. A donor-recipient weight ratio of 4.0 or less was found to be acceptable. The amount of time the graft underwent cold ischemia, ranged from 64 to 576 minutes. The procurement process was facilitated by a single dose of cold crystalloid cardioplegic solution and cold immersion transport. Profound hypothermic circulatory arrest was used for graft implantation. One hundred twenty-four (89%) recipients survived transplantation and were discharged from the hospital. There were 9 late deaths, which resulted in an 83% overall survival. The 5-year actuarial survival is 80%. The survival among newborn recipients (n = 60) at 5 years is 84%. Chronic immunomodulation was cyclosporine-based and steroid-free. Surveillance was noninvasive and relied heavily on echocardiography, electrocardiography, and clinical intuition. There was one documented late lethal infection, tumor was not encountered, and coronary occlusive disease was known to exist in only one long-term survivor. We concluded that transplantation results in excellent life quality and is a highly effective and durable therapy when applied during early infancy.
婴儿早期对心脏移植治疗的兴趣迅速增长。每年登记等待移植的婴儿中有10%至25%在等待供体心脏时死亡。这一变量没有显著趋势。自1985年11月以来,对139名年龄在3小时至12个月的婴儿连续进行了140例原位移植手术。移植指征包括左心发育不全综合征(63%)、其他复杂结构异常(29%)、肌病(6.5%)和肿瘤(1.5%)。大多数受者有动脉导管依赖循环,并接受前列腺素E1持续输注。心脏供体通常是外伤、婴儿猝死或出生窒息的受害者。发现供体与受体体重比为4.0或更低是可以接受的。移植物经历冷缺血的时间为64至576分钟。单剂量冷晶体心脏停搏液和冷浸泡运输有助于获取过程。采用深度低温循环停搏进行移植物植入。124名(89%)受者移植后存活并出院。有9例晚期死亡,总体生存率为83%。5年预期生存率为80%。新生儿受者(n = 60)5年生存率为84%。慢性免疫调节以环孢素为基础且无类固醇。监测是非侵入性的,严重依赖超声心动图、心电图和临床直觉。有1例记录在案的晚期致命感染,未发现肿瘤,已知仅1名长期存活者存在冠状动脉闭塞性疾病。我们得出结论,心脏移植可带来优异的生活质量,在婴儿早期应用时是一种高效且持久的治疗方法。